(NASDAQ: TIVC) is a clinical-stage immunotherapeutics company specializing in Toll-like Receptor 5 (TLR5) agonists. Its lead candidate, Entolimod™, is a late-stage TLR5 agonist being developed primarily as a medical countermeasure for Acute Radiation Syndrome (ARS), with additional potential applications in oncology supportive care and neutropenia. Tivic is actively engaging with international and U.S. government bodies on Entolimod’s potential for national preparedness programs.
On or around April 1, 2026, Tivic is scheduled to discuss or release updates related to its quarterly performance, with consensus projections indicating an EPS loss and revenue near $460,000. The company has been transitioning away from its prior non-core activities while building its biopharma capabilities, including through its wholly-owned CDMO, Velocity Bioworks.
Tivic’s strategic shift toward a pure-play immunotherapy focus has been central to its recent efforts. The company has emphasized advancing the Entolimod platform, securing worldwide rights, delivering significant manufacturing scale-up, and progressing regulatory and partnership discussions. CEO Michael K. Handley (appointed in March 2026) has highlighted the importance of these initiatives in positioning Tivic for future growth in the immunotherapy and medical countermeasure space.
The Ukrainian Ministry of Health’s RFI and interest in Entolimod underscore its potential as a radiation countermeasure. Tivic is collaborating on pathways toward potential accelerated approval and stockpiling agreements. This international engagement complements ongoing U.S. discussions and supports Tivic’s broader strategic goals.
Tivic’s financial results for the year ended December 31, 2025, reflect the costs associated with its clinical-stage focus and transformation. The company reported low revenue (consistent with limited commercial operations during the pivot), gross margins impacted by scaling activities, and a net loss in the mid-to-high single-digit millions. Despite these typical development-stage expenses, Tivic ended 2025 with improved liquidity following recent financings, providing a runway to advance its Entolimod program.
